OCERA'S AST-120 MOVES TO PHASE III TRIAL

Ocera Therapeutics has moved its compound, AST-120, into pivotal development in patients with fistulizing Crohn's disease.

An initial Phase III study is taking place in North America and Europe, recruiting 240 patients who are being randomized to receive treatment or placebo. Its primary endpoint is testing AST-120's ability to cut the number of draining fistulas in half after four weeks and eight weeks of treatment.